Clinical Characteristics and Glycemic Outcomes of Patients with Type 2 Diabetes Requiring Maximum Dose Insulin Glargine/Lixisenatide Fixed-Ratio Combination or Insulin Glargine in the LixiLan-L Trial.

Blonde L, Bailey TS, Chao J, Dex TA, Frias JP, Meneghini LF, Roberts M, Aroda VR

Advances in therapy29 Jul 2019Cited by 2 (Europe PMC)

PMID31359368PMCIDPMC6822975DOI10.1007/s12325-019-01033-1PepBankPUB-31359368

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanNon-randomized trialEfficacy outcome
In diabetes patients receiving 60 units/day, iGlarLixi reduced A1C significantly more than insulin glargine.
In plain wordsIn patients receiving the maximum dose, iGlarLixi reduced A1C more than insulin glargine.
Peptide
Lixisenatide
Outcome
DecreaseA1C change, maximum dose stratum
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Source sentences
Summary
In both dose groups, A1C change from baseline was significantly greater with iGlarLixi vs. iGlar, and more participants treated with iGlarLixi vs. iGlar achieved A1C < 7.0%.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis of the phase 3 LixiLan-L trial (NCT02058160) investigated baseline characteristics, glycemic control, and safety outcomes in participants who received the study-specified maximum dose (60 units/day) of iGlarLixi or iGlar vs. those who received < 60 units/day.
Summary · context
Outcomes were compared for participants receiving 60 or < 60 units/day at week 30.
Report a problemFND-3135936801
02HumanNon-randomized trialEfficacy outcome
In diabetes patients receiving <60 units/day, iGlarLixi reduced A1C significantly more than insulin glargine.
In plain wordsIn patients receiving lower doses, iGlarLixi reduced A1C more than insulin glargine.
Peptide
Lixisenatide
Outcome
DecreaseA1C change, lower dose stratum
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Source sentences
Summary
In both dose groups, A1C change from baseline was significantly greater with iGlarLixi vs. iGlar, and more participants treated with iGlarLixi vs. iGlar achieved A1C < 7.0%.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis of the phase 3 LixiLan-L trial (NCT02058160) investigated baseline characteristics, glycemic control, and safety outcomes in participants who received the study-specified maximum dose (60 units/day) of iGlarLixi or iGlar vs. those who received < 60 units/day.
Summary · context
Outcomes were compared for participants receiving 60 or < 60 units/day at week 30.
Report a problemFND-3135936802
03HumanNon-randomized trialEfficacy outcome
In diabetes patients receiving 60 units/day, more reached A1C <7.0% with iGlarLixi than insulin glargine.
In plain wordsAt the maximum dose, more patients reached the A1C target with iGlarLixi than insulin glargine.
Peptide
Lixisenatide
Outcome
IncreaseA1C target, maximum dose stratum
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Source sentences
Summary
In both dose groups, A1C change from baseline was significantly greater with iGlarLixi vs. iGlar, and more participants treated with iGlarLixi vs. iGlar achieved A1C < 7.0%.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis of the phase 3 LixiLan-L trial (NCT02058160) investigated baseline characteristics, glycemic control, and safety outcomes in participants who received the study-specified maximum dose (60 units/day) of iGlarLixi or iGlar vs. those who received < 60 units/day.
Summary · context
Outcomes were compared for participants receiving 60 or < 60 units/day at week 30.
Report a problemFND-3135936803
04HumanNon-randomized trialEfficacy outcome
In diabetes patients receiving <60 units/day, more reached A1C <7.0% with iGlarLixi than insulin glargine.
In plain wordsAt lower doses, more patients reached the A1C target with iGlarLixi than insulin glargine.
Peptide
Lixisenatide
Outcome
IncreaseA1C target, lower dose stratum
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Glycemic control · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Source sentences
Summary
In both dose groups, A1C change from baseline was significantly greater with iGlarLixi vs. iGlar, and more participants treated with iGlarLixi vs. iGlar achieved A1C < 7.0%.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis of the phase 3 LixiLan-L trial (NCT02058160) investigated baseline characteristics, glycemic control, and safety outcomes in participants who received the study-specified maximum dose (60 units/day) of iGlarLixi or iGlar vs. those who received < 60 units/day.
Summary · context
Outcomes were compared for participants receiving 60 or < 60 units/day at week 30.
Report a problemFND-3135936804
05HumanObservational studyEfficacy outcome
In diabetes patients receiving 60 units/day, iGlarLixi produced modest weight loss versus weight gain with insulin glargine.
In plain wordsAt the maximum dose, patients lost weight with iGlarLixi versus weight gain with insulin glargine.
Peptide
Lixisenatide
Outcome
DecreaseBody weight, maximum dose stratum
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Source sentences
Summary
Participants treated with iGlarLixi (< 60 or 60 units/day) had modest weight loss over 30 weeks vs. an increase in weight compared with iGlar.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis of the phase 3 LixiLan-L trial (NCT02058160) investigated baseline characteristics, glycemic control, and safety outcomes in participants who received the study-specified maximum dose (60 units/day) of iGlarLixi or iGlar vs. those who received < 60 units/day.
Summary · context
Outcomes were compared for participants receiving 60 or < 60 units/day at week 30.
Report a problemFND-3135936805
06HumanObservational studyEfficacy outcome
In diabetes patients receiving <60 units/day, iGlarLixi produced modest weight loss versus weight gain with insulin glargine.
In plain wordsAt lower doses, patients lost weight with iGlarLixi versus weight gain with insulin glargine.
Peptide
Lixisenatide
Outcome
DecreaseBody weight, lower dose stratum
Study
n: not reported in source
Comparator
Insulin glargine
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated · 30 weeksAs given in this study (human).
Source sentences
Summary
Participants treated with iGlarLixi (< 60 or 60 units/day) had modest weight loss over 30 weeks vs. an increase in weight compared with iGlar.
2 context sentences(design, population, supporting numbers)
Summary · context
This post hoc analysis of the phase 3 LixiLan-L trial (NCT02058160) investigated baseline characteristics, glycemic control, and safety outcomes in participants who received the study-specified maximum dose (60 units/day) of iGlarLixi or iGlar vs. those who received < 60 units/day.
Summary · context
Outcomes were compared for participants receiving 60 or < 60 units/day at week 30.
Report a problemFND-3135936806

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT02058160

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

Sanofin = 736Jan 2014 to Jul 2015

Type 2 Diabetes

Trial page ClinicalTrials.govUpdated 9 May 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:36 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.